The exciting part here is this is validation of the tech, with...

The exciting part here is this is validation of the tech, with many other potential use cases. Pre-eclampsia market opportunity estimated at $1.88bil. Further opportunities identified;

Remote Patient Monitoring - $175 bil

Health Wearables - $104bil

Decentralized Clinical Trials - $14bil

Hypertension and arterial healthmonitoring - $1.18bil

Monitoring and management ofheart failure patients - $3.32bil

A Dementia Therapeutic Program - $4bil

The blue sky potential here is excellent for a company valued at ~$22mil, with strong tech validation on the cusp of commercialising their product which has been years of development.

https://hotcopper.com.au/threads/ann-cdx-january-2024-webinar-presentation.7806625/

I'll settle for first sales in December, looking forward to an update in the quarterly. Nice to see Scarlett a bit more chipper with a slight bump in share price, can only imagine the excitement in future!